Oxford Biomedica PLC Hardman & Co Res: BIVV deal establishes structure
28 February 2018 - 6:15PM
RNS Non-Regulatory
TIDMOXB
Oxford Biomedica PLC
28 February 2018
Hardman & Co Res: BIVV deal establishes structure
Bioverativ deal - establishes structure: Oxford BioMedica (OXB)
is a specialist advanced therapy lentivirus-based vector biopharma
company. It offers vector manufacturing and development services
and is developing its own proprietary drug candidates. In addition
to LentiVector(R) service contracts, OXB will receive royalties on
commercial therapies developed with its platform. This deal
structure was established with Novartis for Kymriah(TM), the first
approved CAR-T therapy, and has now been followed by a
collaboration and licence agreement adopting a similar structure
with Bioverativ Inc (BIVV), for the development and potential
clinical supply of vector to treat haemophilia.
Please click here for the full report:
http://hardmanandco.com/docs/default-source/company-docs/oxford-biomedica-documents/28.02.18-bioverativ-deal-establishes-structure.pdf
To contact us: Contacts: mh@hardmanandco.com
Hardman & Co Dr Martin dmh@hardmanandco.com
35 New Broad Street Hall gp@hardmanandco.com
London Dr Dorothea
EC2M 1NH Hill
www.hardmanandco.com Dr Gregoire
Follow us on Twitter Pave
@HardmanandCo
+44 20 7194
7622
About Hardman & Co: For the past 21 years Hardman has been
producing specialist research designed to improve investors'
understanding of companies, sectors, industries and investment
securities. Our analysts are highly experienced in their sectors,
and have often been highly rated by professional investors for
their knowledge. Our focus is to raise companies' profiles across
the UK and abroad with outstanding research, investor engagement
programmes and advisory services. Some of our notes have been
commissioned by the company which is the subject of the note; this
is clearly stated in the disclaimer where this is the case.
Hardman Research Ltd, trading as Hardman & Co, is an
appointed representative of Capital Markets Strategy Ltd and is
authorised and regulated by the Financial Conduct Authority; our
FCA registration number is 600843. Hardman Research Ltd is
registered at Companies House with number 8256259.
Our research is provided for the use of the professional
investment community, market counterparties and sophisticated and
high net worth investors as defined in the rules of the regulatory
bodies. It is not intended to be made available to unsophisticated
retail investors. Anyone who is unsure of their categorisation
should consult their professional advisors. This research is
neither an offer, nor a solicitation, to buy or sell any security.
Please read the note for the full disclaimer.
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRAEAPAXAAEPEFF
(END) Dow Jones Newswires
February 28, 2018 02:15 ET (07:15 GMT)
Oxford Biomedica (LSE:OXB)
Historical Stock Chart
From Apr 2024 to May 2024
Oxford Biomedica (LSE:OXB)
Historical Stock Chart
From May 2023 to May 2024